Sequential anti-cancer treatment

Patent metadata

Field	Value
Publication number	US-10744171-B2
Application number	US-201716086735-A
Country	US
Kind code	B2
Filing date	Mar 20, 2017
Priority date	Mar 21, 2016
Publication date	Aug 18, 2020
Grant date	Aug 18, 2020

Abstract

Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Sequential treatment with the virus construct followed by chemotherapy drugs increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioblastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.

First claim

The invention claimed is:

1. A method of treating a progressing tumor in a patient, comprising:
administering to the patient with a progressing tumor a chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5′ untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame, wherein the patient has been previously treated with a lymphodepleting chemotherapeutic agent; and
administering a lymphodepleting chemotherapeutic agent to the patient when growth of the tumor progresses after the chimeric poliovirus construct is administered.

2. The method of claim 1 wherein the lymphodepleting chemotherapeutic agent causes transient lymphopenia.

3. The method of claim 1 wherein the chemotherapeutic agent is an alkylating agent.

4. The method of claim 1 wherein the chemotherapeutic agent is lomustine.

5. The method of claim 1 wherein the chemotherapeutic agent is temozolomide.

6. The method of claim 1 wherein the chemotherapeutic agent is administered according to a metronomic schedule.

7. The method of claim 6 wherein the chemotherapeutic agent is temozolomide.

8. The method of claim 1 wherein the chemotherapeutic agent is administered at least 3 months after administering of the chimeric poliovirus construct.

9. The method of claim 1 wherein the chemotherapeutic agent is administered at least 5 months after administering of the chimeric poliovirus construct.

10. The method of claim 1 wherein the chemotherapeutic agent is administered at least 7 months after administering of the chimeric poliovirus construct.

11. The method of claim 1 wherein progression of the tumor is assessed by imaging.

12. The method of claim 1 wherein progression of the tumor is assessed by clinical indices.

13. The method of claim 1 wherein the tumor is a brain tumor.

14. The method of claim 13 wherein the tumor is a glioblastoma.

15. The method of claim 13 wherein the tumor is astrocytoma or oligodendroglioma.

16. The method of claim 13 wherein the tumor is astro-oligodendroglioma.

17. The method of claim 13 wherein the tumor is medulloblastoma.

18. The method of claim 1 wherein the tumor is selected from the group consisting of renal cell carcinoma, prostate tumor, bladder tumor, esophagus tumor, stomach tumor, pancreas tumor, colorectal tumor, liver or gall bladder tumor, breast tumor, lung tumor, head and neck tumor, melanoma, and sarcoma.

19. The method of claim 1 wherein the tumor expresses NECL5 (nectin-like protein 5).

20. The method of claim 13 wherein the chimeric poliovirus construct is administered by intracerebral infusion with convection enhanced delivery.

21. The method of claim 1 which comprises the step of: prior to the step of administering the poliovirus construct, testing the tumor to ascertain that it expresses NECL5.

22. The method of claim 1 wherein the chimeric poliovirus construct is administered directly to the tumor.

23. The method of claim 1 wherein the chimeric poliovirus construct is administered when growth of the tumor progresses.

24. The method of claim 1 wherein the chimeric poliovirus construct is PVS-RIPO.

Assignees

• Univ Duke

Inventors

• Bigner Darell D
• Gromeier Matthias
• Desjardins Annick
• Friedman Henry S
• Friedman Allan H
• Sampson John H

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K31/175

  having the group [IMAGE cpc-sch-A61K-0950.gif] , >N—C(O)—N=N— or[IMAGE cpc-sch-A61K-0951.gif] , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof · CPC title

• A61K35/768 Primary

  Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766 · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C12N2840/203

  having an IRES · CPC title